About Event

What you missed in 2023:

CNS biopharma is rapidly investing in digital technologies to revolutionize clinical identification and monitoring of complex neurological disorders, through more objective, frequent, sensitive, and less invasive measures of movement, speech, and cognition.

Returning to Boston, the 2nd Digital Biomarkers & Clinical Measures in Neurology Summit was the only industry-specific meeting dedicated to developing translatable, scalable, and successful digital technologies and measures specifically to be incorporated into neurological clinical trials.

This was your must-attend meeting tackling the development of digital measures to revolutionize clinical assessments across neurological drug development.

Join Pioneering Digital Health Leaders to Hear From:


On showcasing takeaways from utilizing wearable sensors in decentralized clinical trialsto sensitively measure gait and cognitive disease metrics

CPI logo

To breakdown the journey to regulatory approval of novel digital measures and methods to best instill confidence in regulatory bodies

lilly logo
Teva Logo

To explore the best practices to select and validate disease-specific digital measures in neurological indications with poor anchors


On outlining key design considerations in usability of wearable and non-wearable technologies to maximize patient engagement through clinical data collection


To understand methods in digital measure rationale and design to optimize incorporation of novel measures into existing clinical trial frameworks


On adapting a patient co-centric approach to create clinically meaningful digital measures of movement and gait

Who Will You Meet in 2023?

The 2nd Digital Biomarkers & Clinical Measures in Neurology Summit will bridge the gap between data scientists and biostatisticians optimizing the development and validation of digital measurements, and clinical scientists and digital health leaders tackling industry’s transition to integrate clinically meaningful digital tools into their CNS pipelines.

Don’t miss your chance to meet and network with 80+ digital biomarkers KOLs, data scientists and biostatisticians, digital health pioneers, wearable technology specialists, digital therapeutic developers, patient innovation leaders, and digital regulatory experts.

With AbbVie, Biogen Digital Health, Regeneron, Cognito Therapeutics, and more set to deliver case study presentations, this is your must-attend meeting to hear from leading experts driving the digital revolution of biomarkers and endpoints in CNS clinical trials.


What Your CNS Digital Health Peers Had to Say:

“Excellent opportunity to meet, learn, and collaborate with individuals with a vested interest in digital biomarkers and clinical endpoints for Neurology trials”

Michael Ropacki, Chief Medical Officer, CNS Clinical Development, Oryzon Genomics

“I really look forward to this conference and demonstrating what structured data can provide from real world and how this can improve care and outcomes as well as research and development”

Mark Gudesblatt, Neurologist, South Shore Neurology

“The Digital Biomarkers in Neuro Summit is an excellent opportunity to meet and discuss with pioneers in the field and move our collective knowledge up the field. This is how we will most quickly translate in vitro findings into real benefit for patients, clinicians and payors”

Arvind Tewari, Vice President, Digital Strategy & Operations, ATAI Life Sciences

“This meeting offers excellent opportunities for networking with experts from industry and academia”

Gul Erdemli, Global Program Regulatory Leader, Novartis